Prostate Cell News Volume 2.16 | May 6 2011

Investigational Agent Shows Promise in Reducing Spread of Prostate Cancer
A drug developed to treat Ewing’s Sarcoma may also help prevent human prostate cancer from spreading. [Press release from Georgetown University Medical Center discussing online prepublication in PLoS ONE]

Researchers Find that Aspirin Reduces the Risk of Cancer Recurrence in Some Prostate Cancer Patients
Researchers have concluded there is substantial data suggesting that aspirin improves outcomes in prostate cancer patients who have received radiotherapy. [Press release from Fox Chase Cancer Center discussing research presented at the 93rd Annual Meeting of the American Radium Society]

LABORATORY RESEARCH

WWP2 Is an E3 Ubiquitin Ligase for PTEN
By using a tandem affinity-purification approach, researchers have identified WWP2 (also known as atrophin-1-interacting protein 2, AIP-2) as a PTEN-interacting protein. [Nat Cell Biol]

Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell Cycle Arrest Through REDD1
Researchers identified REDD1 (also known as DDIT4 and RTP801), a negative regulator of mTOR, as a new molecular target of metformin. They showed that metformin increases REDD1 expression in a p53-dependent manner. [Cancer Res]

Differential Regulation of PTEN Expression by Androgen Receptor in Prostate and Breast Cancers
Investigators performed in silico analysis of publicly available microarray data sets from prostate or breast carcinomas. [Oncogene]

Control of Tumor and Microenvironment Cross-Talk by miR-15a and miR-16 in Prostate Cancer
Scientists investigate the role of microRNAs in the tumor-supportive capacity of stromal cells. [Oncogene]

Molecular Chemotherapy and Chemotherapy: A New Front Against Late Stage Hormone Refractory Prostate Cancer
Researchers investigated if a novel combination of purine nucleoside phosphorylase mediated gene-directed enzyme-prodrug therapy with docetaxel against castration resistant prostate cancer has superior efficacy in comparison with the individual treatments. [Clin Cancer Res]

Induction of In Vitro and In Vivo NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma
Investigators compare the impact of various anti-prostate specific membrane antigen immunoligand formats on the therapeutic efficacy against prostate carcinoma cells by activating NK cells via NKG2D. [Mol Cancer Ther]

YK-4-279 Inhibits ERG and ETV1 Mediated Prostate Cancer Cell Invasion
Data demonstrate that YK-4-279 inhibits ERG and ETV1 biological activity in fusion-positive prostate cancer cells leading to decreased motility and invasion. [PLoS One]

CLINICAL RESEARCH

Progression from High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium
Preclinical evidence suggests vitamin E, selenium, and soy protein may prevent progression of high-grade prostatic intraepithelial neoplasia to prostate cancer. This hypothesis was tested in a randomized Phase III double-blind study of daily soy (40 g), vitamin E (800 U), and selenium (200 μg) versus placebo. [J Clin Oncol]

mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer
Using the complementary DNA–mediated annealing, selection, extension, and ligation assay, we measured the mRNA expression of 6,100 genes in prostate tumor tissue in the Swedish Watchful Waiting cohort (n = 358) and Physicians’ Health Study (PHS; n = 109). [J Clin Oncol]

Vitamin D Receptor Protein Expression in Tumor Tissue and Prostate Cancer Progression
Scientists examined protein expression of vitamin D receptor in tumor tissue among 841 patients with prostate cancer in relation to risk of lethal prostate cancer within two prospective cohorts, the Physicians’ Health Study and Health Professionals Follow-Up Study. [J Clin Oncol]

Control of Tumor and Microenvironment Cross-Talk by miR-15a and miR-16 in Prostate Cancer
Researchers investigate the role of microRNAs in the tumor-supportive capacity of stromal cells. They demonstrated that miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed. [Oncogene]

Risk-Adjusted Incidence Rates for Prostate Cancer in the United States
This study compared risk-adjusted incidence rates with conventionally reported incidence rates for prostate cancer. [Prostate]

Nucletron Showcases Five Innovations in Cancer Treatment at ESTRO
Nucletron will feature five new innovations at the ESTRO Anniversary Congress, all designed to meet the growing interest and need to more effectively treat a wide variety of cancers. [Nucletron Press Release]

ZYTIGA™ (Abiraterone Acetate) Receives FDA Approval for Treatment of Metastatic Prostate Cancer After Priority Review
Centocor Ortho Biotech Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ZYTIGA™ (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel. [Centocor Ortho Biotech Inc. Press Release]

GenSpera Completes $2.2 Million Private Placement
GenSpera, Inc. announced that it has completed a private placement for approximately $2.2 million, net of fees. [GenSpera, Inc. Press Release]

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.